A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 04 Sep 2026
At a glance
- Drugs SRP 1002 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
Most Recent Events
- 06 Aug 2025 Planned End Date changed from 1 Sep 2025 to 5 Sep 2025.
- 06 Aug 2025 Planned primary completion date changed from 1 Sep 2025 to 5 Sep 2025.
- 06 Aug 2025 Status changed from recruiting to active, no longer recruiting.